Inhibition of CYP2C9 will increase the bioavailability of torasemide, which will increase the risk of adverse effects [49] such as headaches, dizziness, fluid and electrolyte imbalances (such as hypokalemia), and muscle spasms [50]. The gene discussed is CYP2C9; the disease is Hypokalemia.